Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Accumulated Expenses (2019 - 2026)

Pliant Therapeutics has reported Accumulated Expenses over the past 8 years, most recently at $4.1 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 44.23% to $4.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Mar 2026, down 44.23% year-over-year, with the annual reading at $9.6 million for FY2025, 22.01% down from the prior year.
  • Accumulated Expenses was $4.1 million for Q1 2026 at Pliant Therapeutics, down from $9.6 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $20.3 million in Q3 2022 and troughed at $4.1 million in Q1 2026.
  • The 5-year median for Accumulated Expenses is $8.3 million (2023), against an average of $9.5 million.
  • Year-over-year, Accumulated Expenses skyrocketed 112.97% in 2022 and then crashed 61.13% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $8.7 million in 2022, then rose by 18.03% to $10.2 million in 2023, then rose by 20.88% to $12.4 million in 2024, then fell by 22.01% to $9.6 million in 2025, then tumbled by 57.0% to $4.1 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Accumulated Expenses are $4.1 million (Q1 2026), $9.6 million (Q4 2025), and $8.2 million (Q3 2025).